As announced on 4 August 2020, Navamedic completed the acquisition of marketing authorisations in the Nordics for a portfolio of antibiotics products. The antibiotics in the portfolio, now fully onboarded on Navamedic’s platform, are designed to be given intravenously to patients and are in regular use in hospitals in all the Nordic countries.
In accordance with the plan to roll out antibiotics in the Nordic region, Navamedic has signed an agreement with Icepharma for distribution of the antibiotics products to the Icelandic market.
“The addition of the antibiotics portfolio marked an important milestone for Navamedic and our expanding hospital and prescription drug offering. We are pleased to welcome Icepharma to join us in securing steady supply of these important products to Nordic hospitals,” says Kathrine Gamborg Andreassen, CEO of Navamedic.
The antibiotics in the portfolio are designed to be given intravenously to patients and are currently in regular use in hospitals in all the Nordic countries with an annual turnover of approximately NOK 25 million. This portfolio will strengthen Navamedic´s hospital offering with an important product range. This is an important step in Navamedic´s growth strategy.
Navamedic has recruited Janne Folmoe to the company’s Specialty Pharma commercial team. Folmoe comes with extensive experience from the ACS Dobfar portfolio with focus on tender management, and previous commercial positions in the pharma industry in companies such as Bayer and Mylan. Folmoe will play a key role in the commercial operation with regards to the antibiotics portfolio.